T. Renaud, J.-P. Hurvois, P. Uriac
FULL PAPER
(dd, J ϭ 13.0, 3.0 Hz, 1 H), 4.11 (dd, J ϭ 12.0, 2.0 Hz, 1 H), 4.30
(dd, J ϭ 10.5, 3.5 Hz, 1 H), 6.90 (d, J ϭ 8.0 Hz, 1 H), 7.02 (t, J ϭ
of Pearlman’s catalyst (0.375 g). The desired hydrogen pressure
(7.35·102 Torr) was applied and, after 48 h stirring at room temper-
7.0 Hz, 1 H), 7.24 (t, J ϭ 7.0 Hz, 1 H), 7.39 (d, J ϭ 8.0 Hz, 1 H). ature, the usual workup resulted in the precipitation of the hydro-
Ϫ
13C NMR (D2O, 125 MHz): δ ϭ 45.4, 55.3, 64.7 (2 carbons),
chloride salt of trans-6f (0.401 g, 58%). Ϫ M.p. 170Ϫ175 °C (dec.).
1
113.8, 115.1, 121.1, 126.0, 128.3, 135.1, 153.9. Ϫ HRMS (FAB ϩ):
Ϫ IR (KBr): ν˜ ϭ 1286, 1493, 1644, 2955 (br) cmϪ1. Ϫ H NMR
calcd. for C11H14N3O2 [M ϩ Hϩ] 220.1086; found 220.1086.
(D2O, 300 MHz): δ ϭ 1.10 (d, 3J ϭ 7.0 Hz, 3 H, 8-CH3), 1.32 [dm,
2
2J(9a,9b) ϭ 12.0 Hz, 1 H, 9-Ha], 1.49 [dm, J(7a,7b) ϭ 12.0 Hz, 1
2
3
H, 7-Ha], 1.88 [tm, J(9b,9a) ϭ J(9b,10a) ϭ 12.0 Hz, 1 H, 9-Hb],
1,3,4,10a-Tetrahydro-9-oxy-2-thia-4a,9-diazaphenanthren-10-
ylamine·HCl (6d): Compound 5d (0.570 g, 2.3 mmol) was dissolved
in ethanol (6 mL) and placed in a low-pressure hydrogenator in the
presence of Pearlman’s catalyst (0.3 g). The desired hydrogen pres-
sure (7.35 102 Torr, 1 bar) was applied and, after 24 h stirring at
room temperature, the usual workup led to the precipitation of the
hydrochloride salt of 6d (0.538 g, 99%), m.p. 160Ϫ165 °C (dec.). Ϫ
IR (KBr): ν˜ ϭ 1298, 1502, 1674, 3036 (br) cmϪ1. Ϫ 1H NMR (D2O,
500 MHz): δ ϭ 2.28 (d, J ϭ 13.5 Hz, 1 H), 2.35 (d, J ϭ 13.0 Hz,
1 H), 3.08 (dd, J ϭ 15.5, 11.5 Hz, 1 H), 3.18 (td, J ϭ 13.0, 2.0 Hz,
1 H), 3.56 (ddd, J ϭ 14.0, 12.5, 3.0 Hz, 1 H), 4.28 (d, J ϭ 15.0 Hz,
1 H), 5.00 (dd, J ϭ 11.5, 2.0 Hz, 1 H), 7.00Ϫ7.08 (m, 2 H), 7.31
(t, J ϭ 7.0 Hz, 1 H), 7.47 (d, J ϭ 7.0 Hz, 1 H). Ϫ 13C NMR (D2O,
125 MHz): δ ϭ 19.8, 23.6, 47.1, 59.6, 114.4, 115.2, 119.9, 125.6,
128.5, 133.2, 153.1. Ϫ HRMS (FAB ϩ): calcd. for C11H14N3OS [M
ϩ Hϩ] 236.0858; found 236.0860.
2
3
3
1.98 [td, J(7b,7a) ϭ J(7b,6a) ϭ 12.0 Hz, J(7b,8) ϭ 3.5 Hz, 1 H,
7-Hb], 2.03Ϫ2.15 (m,
1 ϭ
H, 8-H), 3.17 [td, 2J(10a,10b)
3J(10a,9b) ϭ 12.0 Hz, J(10a,9a) ϭ 3.0 Hz, 1 H, 10-Ha], 3.53 [dt,
3
2J(10b,10a) ϭ 12.0 Hz, 3J(10b,9b) ϭ J(10b,9a) ϭ 3.5 Hz, 1 H, 10-
3
Hb], 4.54 [dd, 3J(6a,7b) ϭ 12.0 Hz, 3J(6a,7a) ϭ 3.0 Hz, 1 H, 6a-H],
6.97Ϫ7.03 (m, 2 H), 7.23 (t, 1 H), 7.40 (d, 1 H). Ϫ 13C NMR (D2O,
75 MHz): δ ϭ 19.0, 27.7, 28.6, 33.2, 44.2, 55.9, 117.4, 117.7, 123.2,
129.0, 130.5, 137.4, 159.5.
Ϫ HRMS (FAB ϩ): calcd. for
C13H18N3O [M ϩ Hϩ] 232.1450; found 232.1452.
(6aR*,8S*)-7,8,9,10-Tetrahydro-6aH-8-methyl-5-oxopyrido[1,2-a]-
quinoxalin-6-ylamine·HCl (cis-6f): Compound cis-5f (0.368 g,
1.5 mmol) was dissolved in ethanol (5 mL) and placed in a low-
pressure hydrogenator in the presence of Pearlman’s catalyst (0.368
g). After 5 h stirring at room temperature, the usual workup re-
sulted in the precipitation of the hydrochloride salt of cis-6f (0.242
g, 70%). Ϫ M.p. 175Ϫ180 °C (dec.). Ϫ IR (KBr): ν˜ ϭ 1496, 1648,
3100 (br) cmϪ1. Ϫ 1H NMR (D2O, 300 MHz) δ ϭ 0.82 (d, 3J ϭ
7.0 Hz, 3 H, 8-CH3), 1.11Ϫ1.29 (m, 2 H, 7-Ha, 9-Ha), 1.54 [dm,
Synthesis of 7e: Compound 5e (0.228 g, 0.7 mmol) was dissolved
in a 1:1 mixture of ethanol and dioxane (3.0 mL) and placed in a
low-pressure hydrogenator in the presence of Pearlman’s catalyst
(0.067 g). The desired hydrogen pressure (7.35 ϫ 102 Torr, 1 bar)
was applied and, after 20 h stirring at room temperature, the addi-
tion of diethyl ether resulted in the precipitation of 6e (0.127 g,
60%), which was further purified by rapid filtration through a silica
column, with a mixture (80:20) of dichloromethane and methanol
as eluent. Addition of HCl in ethanol (3 , 8 mL) to the resulting
powder resulted in the precipitation of the hydrochloride salt of 7e.
2
2J(9b,9a) ϭ 14.0 Hz, 1 H, 9-Hb], 1.67 [dm, J(7b,7a) ϭ 14.0 Hz, 1
H, 7-Hb], 1.70Ϫ1.80 (m, 1 H, 8-H), 2.90 [t, 2J(10a,10b) ϭ
3J(10a,9a) ϭ 13.0 Hz, 1 H, 10-Ha], 3.82 [dm, 2J(10b,10a) ϭ
13.0 Hz, 1 H, 10-Hb], 4.31 [dd, 3J(6a,7a) ϭ 12.0 Hz, 3J(6a,7b) ϭ
2.0 Hz, 1 H, 6a-H], 6.89Ϫ6.96 (m, 2 H), 7.19 (t, 1 H), 7.35 (d, 1
H), Ϫ 13C NMR (D2O, 75 MHz): δ ϭ 23.8, 30.9, 33.0, 35.5, 48.4,
60.5, 116.9, 117.4, 122.6, 128.5, 130.5, 137.2, 159.1.
5-Amino-1,2,4,4a-tetrahydropyrazino[1,2-a]quinoxaline-3-carboxylic
Acid tert-Butyl Ester (6e): M.p. 170Ϫ175 °C (dec.). Ϫ Rf ϭ 0.8
(CH2Cl2/MeOH, 80:20). Ϫ IR (KBr): ν˜ ϭ 744, 1654 (CϭN), 1688
6,6a,7,8,9,10-Hexahydro-5H-pyrido[1,2-a]quinoxaline (3a): The am-
idine N-oxide 6a (0.680 g, 3.1 mmol) was dissolved in methanol
(50 mL) and placed in a high-pressure hydrogenation apparatus in
the presence of Pearlman’s catalyst (0.345 g). The desired pressure
(3.75·103 Torr) was applied and the resulting solution was shaken
for 7 days at room temperature. The catalyst was removed by filtra-
tion and washed with methanol. The combined solutions were
evaporated to dryness. The crude material was further chromato-
graphed on silica (eluent: CH2Cl2) to afford 3a as a colorless oil,
which solidified upon cooling (0.33 g, 56%). Ϫ Pale yellow powder,
m.p. 97 °C (diethyl ether/petroleum ether). Ϫ Rf ϭ 0.33 (CH2Cl2).
Ϫ IR (KBr): ν˜ ϭ 740, 1500,3330 cmϪ1 (NH). Ϫ 1H NMR (CDCl3,
500 MHz): δ ϭ 1.24Ϫ1.44 (m, 2 H, 8-Ha and 7-Ha), 1.56Ϫ1.68 (m,
2 H, 7-Hb and 9-Ha), 1.74Ϫ1.84 (m, 2 H, 8-Hb and 9-Hb), 2.53 [td,
1
(CϭO) cmϪ1. Ϫ H NMR (CD3OD, 300 MHz, 55 °C): δ ϭ 1.49
(s, 9 H, (CH3)3ϪC), 2.95Ϫ3.16 (m, 3 H, 1-Ha, 2-Ha, 4-Ha), 3.92
[dm, 2J(1b,1a) ϭ 13.0 Hz, 1 H, 1-Hb], 4.00 [dm, 2J(2b,2a) ϭ
13.0 Hz, 1 H, 2-Hb], 4.24 [dm, 2J(4b,4a) ϭ 13.0 Hz, 1 H, 4-Hb],
4.33 [dd, 3J(4-a,4a) ϭ 11.0 Hz, 2J(4-a,4b) ϭ 4.0 Hz, 1 H, 4a-H],
6.87Ϫ6.95 (m, 2 H), 7.15 (t, 1 H), 7.74 (d, 1 H). Ϫ 13C NMR
(CD3OD, 75 MHz, 55 °C): δ ϭ 28.5 [(CH3)3ϪC], 41.7 (coalescent,
C-2), 44.2 (coalescent, C-4), 46.0 (C-1), 57.1 (C-4a), 82.1
[(CH3)3ϪC], 113.4, 117.7, 120.6, 128.2, (C-7, C-8, C-9, C-10),
129.7, (C-6a), 136.3 (C-10a), 147.3 (C-5), 156.2 (CϭO). Ϫ HRMS
(FAB ϩ): calcd. for C16H23N4O3 [M ϩ Hϩ] 319.1770; found
319.1769.
3
2J(10a,10b) ϭ J(10a,9a) ϭ 12.0 Hz, 3J(10a,9b) ϭ 3.0 Hz, 1 H, 10-
Ha], 2.88Ϫ2.95 (m, 1 H, 6a-H), 3.19Ϫ3.26 (m, 2 H, 6-H),
3.40Ϫ3.50 (s, br., 1 H, NH), 3.80 [dm, 2J(10b,10a) ϭ 12.0 Hz, 1 H,
10-Hb], 6.43 (dd, J ϭ 7.5, 1.5 Hz, 1 H), 6.57Ϫ6.65 (m, 2 H), 6.73
(d, J ϭ 8.0 Hz, 1 H). Ϫ 13C NMR (CDCl3, 75 MHz): δ ϭ 22.6 (C-
8), 24.2 (C-9), 29.0 (C-7), 46.2 (C-10), 46.8 (C-6), 53.2 (C-6a), 111.7
and 113.1 (C-1 or C-4), 117.5 and 117.9 (C-2 or C-3), 134.1 and
134.7 (C-4a or C-10b).
188.1313; found 188.1313. Ϫ C12H16N2: calcd. C 76.55, H 8.57, N
14.88; found C 76.31, H 8.43, N 14.43.
2,3,4,4a-Tetrahydro-1H-6-oxypyrazino[1,2-a]quinoxalin-5-ylamine
(7e): M.p. 200Ϫ205 °C (dec.). Ϫ IR (KBr): ν˜ ϭ 1508, 1602, 1672,
2486, 3006 cmϪ1. Ϫ 1H NMR (D2O, 300 MHz): δ ϭ 3.30Ϫ3.60
(m, 5 H), 4.22 (d, J ϭ 15.0 Hz, 1 H), 5.06 (dd, J ϭ 11.0, 3.0 Hz, 1
H), 7.07 (d, 1 H), 7.13 (t, 1 H), 7.36 (t, 1 H), 7.53 (d, 1 H). Ϫ 13C
NMR (D2O, 75 MHz): δ ϭ 42.0, 43.1, 44.7, 56.6, 116.5, 118.2,
123.9, 128.3, 131.2, 135.1, 154.4. Ϫ HRMS (FAB ϩ): calcd. for
C11H15N4O [M ϩ Hϩ] 219.1246; found 219.1246.
Ϫ
HRMS (C12H16N2 [Mϩ]): calcd.
(6aR*,8R*)-7,8,9,10-Tetrahydro-6aH-8-methyl-5-oxopyrido[1,2-
a]quinoxalin-6-ylamine·HCl (trans-6f): Compound trans-5f (0.736 g, 5,6,6a,7,8,9,10,11-Octahydroazepino[1,2-a]quinoxaline (3b): Com-
3.0 mmol) was dissolved in a 1:1 mixture of ethanol and dioxane
(3.0 mL) and placed in a low-pressure hydrogenator in the presence
pound 6b (0.5 g, 2.16 mmol) was dissolved in methanol (35 mL),
and placed in a high-pressure apparatus in the presence of
994
Eur. J. Org. Chem. 2001, 987Ϫ996